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Summary
Background A previous aggregate data meta-analysis of randomised controlled trials showed that vitamin D 
supplementation reduces the rate of asthma exacerbations requiring treatment with systemic corticosteroids. 
Whether this effect is restricted to patients with low baseline vitamin D status is unknown.
Methods For this systematic review and one-step and two-step meta-analysis of individual participant data, we 
searched MEDLINE, Embase, the Cochrane Central Register of Controlled Trials, and Web of Science for double-blind, 
placebo-controlled, randomised controlled trials of vitamin D3 or vitamin D2 supplementation in people with asthma 
that reported incidence of asthma exacerbation, published between database inception and Oct 26, 2016. We analysed 
individual participant data requested from the principal investigator for each eligible trial, adjusting for age and sex, 
and clustering by study. The primary outcome was the incidence of asthma exacerbation requiring treatment with 
systemic corticosteroids. Mixed-effects regression models were used to obtain the pooled intervention effect with a 
95% CI. Subgroup analyses were done to determine whether effects of vitamin D on risk of asthma exacerbation 
varied according to baseline 25-hydroxyvitamin D (25[OH]D) concentration, age, ethnic or racial origin, body-mass 
index, vitamin D dosing regimen, use of inhaled corticosteroids, or end-study 25(OH)D levels; post-hoc subgroup 
analyses were done according to sex and study duration. This study was registered with PROSPERO, number 
CRD42014013953.
Findings Our search identified 483 unique studies, eight of which were eligible randomised controlled trials (total 
1078 participants). We sought individual participant data for each and obtained it for seven studies (955 participants). 
Vitamin D supplementation reduced the rate of asthma exacerbation requiring treatment with systemic corticosteroids 
among all participants (adjusted incidence rate ratio [aIRR] 0·74, 95% CI 0·56–0·97; p=0·03; 955 participants in 
seven studies; high-quality evidence). There were no significant differences between vitamin D and placebo in the 
proportion of participants with at least one exacerbation or time to first exacerbation. Subgroup analyses of the rate of 
asthma exacerbations treated with systemic corticosteroids revealed that protective effects were seen in participants 
with baseline 25(OH)D of less than 25 nmol/L (aIRR 0·33, 0·11–0·98; p=0·046; 92 participants in three studies; 
moderate-quality evidence) but not in participants with higher baseline 25(OH)D levels (aIRR 0·77, 0·58–1·03; 
p=0·08; 764 participants in six studies; moderate-quality evidence; pinteraction=0·25). p values for interaction for all other 
subgroup analyses were also higher than 0·05; therefore, we did not show that the effects of this intervention are 
stronger in any one subgroup than in another. Six studies were assessed as being at low risk of bias, and one was 
assessed as being at unclear risk of bias. The two-step meta-analysis did not reveal evidence of heterogeneity of effect 
(I²=0·0, p=0·56).
Interpretation Vitamin D supplementation reduced the rate of asthma exacerbations requiring treatment with 
systemic corticosteroids overall. We did not find definitive evidence that effects of this intervention differed across 
subgroups of patients.
Funding Health Technology Assessment Program, National Institute for Health Research (reference number 13/03/25).
Introduction
Asthma affects more than 300 million people worldwide 
and is estimated to cause almost 400 000 deaths 
annually.1,2 Asthma mortality arises primarily during 
episodes of acute worsening of symptoms, termed 
exacerbations, which are commonly precipitated by viral 
upper respiratory infections.3 Virus-induced asthma 
exacerbations are associated with increased production 
of pro-inflammatory cytokines such as interleukin 17A, 
which exacerbate allergic airway responses.4 Vitamin D 
metabolites support antiviral responses in respiratory 
epithelial cells5 and inhibit production of interleukin 17A 
in peripheral blood mononuclear cells isolated 
from patients with severe asthma.6 Low circulating 
concentrations of the major circulating vitamin D 
metabolite, 25-hydroxyvitamin D (25[OH]D), are 
associated with increased risk of asthma exacerbation in 
both children7 and adults,8 and eight double-blind, 
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placebo-controlled, randomised controlled trials (RCTs)9–16 
have been published investigating the effects of 
vitamin D supplementation on the risk of asthma 
exacerbation. So far, six meta-analyses incorporating 
data from trials of vitamin D for the management of 
asthma have been done: four reported protective effects 
of vitamin D supp lementation against asthma 
exacerbation,17–20 one reported no such effect,21 and one 
did not attempt a meta-analysis for the outcome of 
exacerbation.22 The most recent of these, a Cochrane 
systematic review20 and aggregate data meta-analysis 
including data from both children and adults and 
restricted to double-blind, placebo-controlled RCTs 
found that vitamin D supplementation reduced the rate 
of asthma exacerbations requiring treatment with 
systemic corticosteroids by 36%.20 However, insufficient 
access to individual participant data (IPD) meant that 
subgroup analyses could not be done to address the 
question of whether protective effects of vitamin D 
supplementation against asthma exacerbation are 
stronger in individuals with low baseline vitamin D 
status; the theory being that individuals with the lowest 
baseline levels of a micronutrient might be expected to 
derive the greatest benefit from its replacement. In 
keeping with this hypothesis, protective effects of 
vitamin D supplementation against acute respiratory 
infection23 and acute exacerbations of chronic obstructive 
pulmonary disease24,25 have been reported to be 
strongest in individuals with low circulating 25(OH)D 
concentrations. We therefore set out to obtain IPD from 
double-blind, placebo-controlled RCTs investigating the 
effects of vitamin D supple mentation on the risk of 
asthma exacerbation, and then to meta-analyse the data 
to obtain an updated estimate of the overall effectiveness 
of the supplementation and to determine whether the 
effects of this intervention vary according to baseline 
vitamin D status.
Methods
Search strategy and selection criteria
The methods for this systematic review and one-step and 
two-step meta-analysis were described in an outline 
protocol that was registered with the PROSPERO 
International Prospective Register of Systematic Reviews. 
The outline protocol includes populations of people at risk 
of acute respiratory infection, and people with asthma and 
chronic obstructive pulmonary disease. This systematic 
review and meta-analysis of individual participant data 
focuses on people with asthma. A systematic review and 
meta-analysis of individual participant data in people with 
acute respiratory infection has been previously published.23 
Research ethics committee approval was not required in 
the UK to do this meta-analysis; local ethical permission 
to contribute de-identified IPD from primary RCTs was 
required and obtained for studies by Urashima and 
colleagues9 and Tachimoto and colleagues14 (ethics 
committee of the Jikei University School of Medicine). 
Findings are reported according to the PRISMA guidelines 
for IPD meta-analysis.26
Double-blind, placebo-controlled RCTs of supple-
mentation with vitamin D3 or vitamin D2 in patients with 
asthma were eligible for inclusion if they had been 
approved by a research ethics committee and if data on 
incidence of asthma exacerbation were reported.
Research in context
Evidence before this study
Before doing this study, we searched the PROSPERO 
International Prospective Register of Systematic Reviews, 
ClinicalTrials.gov, and MEDLINE for published or ongoing 
meta-analyses of randomised controlled trials of vitamin D 
supplementation in people with asthma, without language 
restrictions, from database inception to Sept 30, 2014, using 
the search terms “vitamin D” and “asthma”. A Cochrane 
meta-analysis of aggregate data from double-blind, 
placebo-controlled, randomised controlled trials found that 
vitamin D supplementation reduced the rate of asthma 
exacerbations requiring treatment with systemic corticosteroids 
(rate ratio 0·64, 95% CI 0·46–0·90). Whether this effect is 
restricted to patients with lower baseline vitamin D status 
(25-hydroxyvitamin D <25 nmol/L) is not known; an individual 
participant data meta-analysis could resolve this issue, but this 
has not previously been done.
Added value of this study
Our meta-analysis of individual participant data from 
955 participants in seven randomised controlled trials provides 
an updated pooled estimate of the protective effects of 
vitamin D against asthma exacerbations requiring treatment 
with systemic corticosteroids overall. Uniquely, our 
meta-analysis also investigates whether the effect of vitamin D 
on risk of asthma exacerbation varies according to baseline 
25-hydroxyvitamin D concentrations.
Implications of all the available evidence
Overall, vitamin D reduced the rate of asthma exacerbations 
treated with systemic corticosteroids, as compared with 
placebo (0·30 events per person per year vs 0·43 events 
per person per year; p=0·03). Subgroup analysis revealed that 
vitamin D reduced the rate of asthma exacerbations treated 
with systemic corticosteroids in people with a baseline 
25-hydroxyvitamin D of less than 25 nmol/L (0·19 events per 
person per year vs 0·42 events per person per year; p=0·046), 
but vitamin D supplementation did not result in a statistically 
significant reduction in exacerbation rate in participants with 
baseline 25-hydroxyvitamin D of 25 nmol/L or higher. We did 
not find definitive evidence that effects of this intervention 
differed across subgroups of patients.
For the study protocol see 
http://www.crd.york.ac.uk/
PROSPERO/display_record.
asp?ID=CRD42014013953
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Two investigators (DAJ and ARM) searched MEDLINE, 
Embase, the Cochrane Central Register of Controlled 
Trials, and Web of Science using the electronic search 
strategies described in the appendix (p 1). We regularly 
updated our searches from database inception up to and 
including Oct 26, 2016. No language restrictions were 
imposed. We supplemented these searches by searching 
review articles and reference lists of trial publications. 
Collaborators were asked if they knew of any additional 
RCTs. Three investigators (DAJ, CAC Jr, and ARM) 
determined which studies met the eligibility criteria.
Data analysis
We requested IPD from the principal investigator for 
each eligible trial, and the terms of collaboration were 
specified in a data transfer agreement, signed by 
representatives of the data provider and the recipient 
(Queen Mary University of London). Data were 
de-identified at source before transfer via email. On 
receipt, three investigators (DAJ, RLH, and LG) assessed 
data integrity by doing internal consistency checks and 
by attempting to replicate results of the analysis for 
incidence of asthma exacerbations where this was 
published in the trial report. We contacted study authors 
to obtain missing data and to resolve queries arising 
from these integrity checks. Once queries had been 
resolved, clean data were uploaded to the main study 
database, which was held in STATA IC version 12 (College 
Station, TX, USA).
We extracted data relating to study characteristics for 
the following variables: setting, eligibility criteria, 
details of intervention and control regimens, and study 
duration. Where available, we extracted IPD for certain 
variables relating to baseline characteristics and 
follow-up data. Baseline data were requested for age, 
sex, racial or ethnic origin, weight, height, serum 25(OH)
D concentration, study allocation (vitamin D vs placebo), 
and details of stratification variables if applicable. 
Follow-up data were requested for the total number of 
asthma exacerbations requiring treatment with systemic 
corticosteroids, resulting in emergency department 
attendance or hospital admission, or both, and as 
defined in the trial protocol; time from first dose of 
study drug to first asthma exacerbation requiring 
treatment with systemic corticosteroids; occurrence of 
serious adverse events and potential adverse reactions 
to vitamin D supplementation (hypercalcaemia or renal 
stones); serum 25(OH)D concentration at final follow-up; 
and duration of participant follow-up.
We used the Cochrane Collaboration Risk of Bias tool27 
to assess the following variables: sequence generation; 
allocation concealment; blinding of participants, 
personnel, and outcome assessors; completeness of out-
come data; evidence of selective outcome reporting; and 
other potential threats to validity. We assessed selectivity 
of reporting either by comparing study protocols against 
study reports or by specifically asking study authors 
whether all prespecified outcomes were reported. 
Two investigators (ARM and DAJ) independently 
assessed study quality, except for the trial by Martineau 
and colleagues,12 which was assessed by CAC Jr. 
Discrepancies were resolved by consensus.
The primary outcome of the meta-analysis was 
incidence of asthma exacerbation requiring treatment 
with systemic corticosteroids. We selected this outcome 
on the basis that requirement for systemic corticosteroids 
is a widely recognised indicator of exacerbation severity.28 
We measured the primary outcome as rate of asthma 
exacerbations, proportion of participants with at least 
one exacerbation, and time to first exacerbation. 
Secondary outcomes were incidence of exacerbations 
resulting in emergency department attendance or 
hospital admission, or both; incidence of exacerbations 
as defined in the protocol of the primary trial; incidence 
of serious adverse events; incidence of potential adverse 
reactions to vitamin D (hypercalcaemia and renal stones); 
and mortality (asthma related and all cause).
Effects of the intervention on event rates, dichotomous 
outcomes, and time to first event were expressed as rate 
ratios (RRs), odds ratios (ORs), and hazard ratios (HRs), 
respectively. LG, DAJ and RLH analysed the data. Our 
IPD meta-analysis approach followed published 
guidelines.29 Initially, all studies were reanalysed 
separately; the original authors were asked to confirm 
accuracy of this reanalysis where it had been done 
previously, and any discrepancies were resolved. Then, 
for each outcome separately, we did both one-step and 
two-step IPD meta-analyses. In the one-step approach, 
IPD from all studies were modelled simultaneously 
while accounting for the clustering of participants 
within studies. We used mixed models, with a random 
effect for study and fixed effects for age and sex, to 
obtain the pooled intervention effect with a 95% CI. We 
analysed event rates using mixed-effect Poisson 
regression; proportions using mixed-effects logistic 
regression, additionally adjusted for duration of 
participant follow-up; and survival data using 
mixed-effects parametric survival models. We did not 
adjust for other covariates because missing values for 
some participants would have led to their exclusion 
from statistical analyses. In the two-step approach, IPD 
were first analysed for each separate study 
independently to produce an estimate of the treatment 
effect for that study. We analysed event rates using 
Poisson regression, with adjustment for age and sex; 
proportions using logistic regression with adjustment 
for age, sex, and duration of participant follow-up; and 
survival data using parametric survival models, with 
adjustment for age and sex. We then calculated a 
weighted average of the individual treatment effect 
estimates using the DerSimonian and Laird procedure 
for random-effects meta-analysis.30 For the two-step 
IPD meta-analysis, we summarised heterogeneity 
using the I² statistic.
See Online for appendix
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To investigate the causes of heterogeneity and identify 
factors modifying the effects of vitamin D supple-
mentation, we did prespecified subgroup analyses by 
extending the one-step meta-analysis framework to include 
treatment-covariate interaction terms. Subgroups were 
defined according to baseline vitamin D status (serum 
25[OH]D <25 nmol/L vs ≥25 nmol/L), age (<16 years vs 
≥16 years), ethnic or racial origin (African-American, 
Afro-Caribbean, or black African origin vs Asian origin vs 
white European origin vs other or mixed origin), body-mass 
index (<25 kg/m² vs ≥25 kg/m²), vitamin D dosing regimen 
(daily or weekly administration without bolus dosing vs 
administration of a regimen including at least one bolus 
dose of at least 30 000 IU vitamin D), dose size (daily 
equivalent <2000 IU vs ≥2000 IU), and concomitant 
asthma treatment (use of inhaled corticosteroids vs not). 
The 25 nmol/L cutoff for baseline 25(OH)D concentration 
in the subgroup analyses was selected because it is the 
threshold for vitamin D deficiency defined by the UK 
Department of Health31 and because, below this level, 
vitamin D supplementation protects most strongly against 
acute respiratory infection.23 We also did an exploratory 
analysis investigating effects in subgroups defined using 
the 50 nmol/L and 75 nmol/L cutoffs for baseline 
circulating 25(OH)D concentration because observational 
studies have reported that less profound states of vitamin D 
deficiency might associate independently with increased 
risk of asthma exacerbation.7,8 We also did exploratory 
subgroup analyses by sex and study duration (<6 months 
vs ≥6 months) in response to comments from reviewers. 
Statistical significance was inferred for subgroup effects in 
which the p value for the treatment-covariate interaction 
terms was less than 0·05. We did a responder analysis in 
participants randomly assigned to the intervention arm of 
included studies for whom end-study 25(OH)D data were 
available, comparing risk of asthma exacerbations treated 
with systemic corticosteroids in participants who attained 
a serum 25(OH)D of 75 nmol/L or higher vs participants 
who did not.
For the primary analysis of rate of exacerbations 
requiring systemic steroids, the likelihood of publication 
bias was investigated through the construction of a 
contour-enhanced funnel plot.32 We used the five GRADE 
considerations (study limitations, consistency of effect, 
imprecision, indirectness, and publication bias)33 to 
assess the quality of the body of evidence contributing to 
the principal analyses of rate of exacerbations requiring 
systemic steroids, the proportion of participants with at 
least one exacerbation requiring emergency department 
attendance or hospital admission, or both, and the 
proportion of participants with at least one serious 
adverse event.
Data were analysed using STATA IC, version 12. This 
study was registered with the PROSPERO, number 
CRD42014013953.
Role of the funding source
The National Institute of Health Research had no role in 
study design, data collection, data analysis, or data in-
terpretation, or writing of the report. The corresponding 
author had full access to all the data in the study and had 
final responsibility for the decision to submit for 
publication.
Results
Our search identified 483 unique studies that we assessed 
for eligibility, of which eight studies with a total of 
1078 randomly assigned participants fulfilled eligibility 
criteria (figure 1). We sought IPD for all eight studies, 
which we obtained for seven (total 978 participants); data 
were not obtained for one study (100 participants) because 
the corresponding author did not respond to invitations 
to contribute IPD to this meta-analysis. Outcome data 
were obtained for 955 (98%) of 978 randomly assigned 
participants in these seven studies.
The seven analysed RCTs were done in six different 
countries on three continents, and enrolled participants of 
both sexes aged 1·6–85·0 years (table 1). Five RCTs with a 
total of 297 included participants enrolled children, and 
two RCTs with a total of 658 included participants enrolled 
adults (table 1). Baseline serum 25(OH)D concentrations 
were determined in six RCTs, ranging from undetectable 
to 187·2 nmol/L; table 1). All studies administered oral 
Figure 1: Study selection
483 unique studies
8 eligible studies with a total of 1078 randomly
assigned participants (individual participant
data sought for all)
7 able to obtain individual participant data
(978 participants, of whom 955 [98%] had
outcome data available for analysis)
293 duplicates removed
1 unable to obtain individual participant
data (100 participants)
776 potentially eligible studies identified through
database searching
270 MEDLINE
165 Cochrane Central
106 Embase
235 Web of Science
475 excluded 
374 not relevant
 45 review articles
 34 not double-blind, randomised,
 placebo-controlled trials
 22 data on acute asthma exacerbation
 not reported
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vitamin D3 to participants in the intervention arm: this 
was given as a bolus dose every 2 months in one study 
(100 000 IU per bolus); as a daily dose in four studies 
(ranging from 500 IU/day to 2000 IU/day; and as a 
combination of bolus and daily doses in two studies 
(100 000 IU bolus then 400–4000 IU/day). Study durations 
ranged from 15 weeks to 1 year. Details of the number of 
asthma exacerbations treated with systemic corticosteroids 
and the proportion of participants experiencing at least 
one such event by arm and study are presented in 
appendix (p 3). In two RCTs,9,10 no asthma exacerbations 
requiring treatment with systemic corticosteroids arose, 
and in one trial,14 only one asthma exacerbation requiring 
treatment with systemic corticosteroids arose. Effect 
estimates could not be calculated for these three studies 
individually; accordingly, these studies contributed data to 
the one-step, but not the two-step, meta-analyses.
IPD integrity was confirmed by replication of primary 
analyses in published papers where applicable. The 
process of checking IPD revealed two discrepancies with 
primary reports. In the trial by Urashima and colleagues,9 
the relative risk for asthma exacerbation was calculated 
using denominators based on the study population as a 
whole, irrespective of whether or not the participants had 
asthma (n=334). By contrast, we calculated this figure 
using denominators based on the number of children 
with asthma for whom outcome data were available 
(n=99). In the trial by Castro and colleagues,11 IPD 
detailed 14 serious adverse events arising in participants 
randomly assigned to placebo, as compared with 13 such 
events reported in the published manuscript.
Details of the risk of bias assessment are provided in 
appendix (p 4). All RCTs, but one, were assessed as being 
at low risk of bias for all aspects analysed. The trial by 
Kerley and colleagues16 was assessed as being at unclear 
risk of bias due to its high rate of loss to follow-up (12 of 
51 participants), although we found no evidence to 
suggest differential rates of loss to follow-up between the 
intervention and control arms (seven of 24 participants vs 
five of 27).
Overall, in the one-step IPD meta-analysis, vitamin D 
supplementation resulted in a significant reduction in the 
rate of asthma exacerbations requiring treatment with 
systemic corticosteroids (adjusted incidence RR [aIRR] 0·74, 
95% CI 0·56–0·97; p=0·03; 955 participants in 
seven studies; table 2). This evidence was assessed as being 
of high quality (appendix p 5). The two-step IPD 
meta-analysis revealed a similar effect size among 
719 participants in four studies (aIRR 0·69, 0·52–0·92, 
p=0·01; pheterogeneity=0·56; figure 2). In the analyses of the 
proportion of participants with at least one asthma 
exacerbation treated with systemic corticosteroids, the 
effect estimates favoured vitamin D but the differences 
between groups were not significant, in both the one-step 
analysis (adjusted OR [aOR] 0·75, 95% CI 0·51–1·09, 
p=0·13; 955 participants in seven studies) and two-step 
analysis (aOR 0·69, 0·46–1·02, p=0·06; pheterogeneity=0·74; 
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719 participants in four studies; appendix p 8). Similarly, for 
the analyses of time to first exacerbation, the effect 
estimates favoured vitamin D but the differences between 
groups were not significant, in both the one-step analysis 
(adjusted HR [aHR] 0·78, 95% CI 0·55–1·10; p=0·16; 
868 participants in five studies) and two-step analysis 
(aHR 0·74, 0·52–1·05, p=0·09; pheterogeneity=0·58; 
680 participants in three studies; appendix p 9).
We did subgroup analyses to investigate whether the 
effects of vitamin D supplementation on rate of asthma 
exacerbations requiring treatment with systemic 
corticosteroids differed according to baseline vitamin D 
status, age, ethnic or racial origin, body-mass index, 
administration of bolus-dose vitamin D, amount of 
vitamin D administered, and concomitant use of inhaled 
corticosteroids (table 2). We also did exploratory post-hoc 
subgroup analyses by sex and study duration (table 2). 
Vitamin D supplementation significantly reduced the 
rate of asthma exacerbations treated with systemic 
corticosteroids in individuals with baseline circulating 
25(OH)D of less than 25 nmol/L (aIRR 0·33, 95% CI 
0·11–0·98; 92 participants in three studies; within 
subgroup p=0·046; table 2). Vitamin D supplementation 
did not result in a statistically significant reduction in 
exacerbation rate in participants with baseline 25(OH)D 
of 25 nmol/L or higher (aIRR 0·77, 0·58–1·03; 
764 participants in six studies; within subgroup p=0·08). 
The treatment-covariate interaction term (ratio of aIRRs) 
for this subgroup analysis was 0·56 (95% CI 0·20–1·52, 
pinteraction=0·25). Quality assessments of these within-
Number of 
participants; 
number of trials*
Event rate per 
participant-year 
(control group)
Event rate per 
participant-year 
(intervention group)
Adjusted incidence 
rate ratio (95% CI)†
p value pinteraction‡
Overall 955; 7 121/284·7 (0·43) 85/286·6 (0·30) 0·74 (0·56–0·97) 0·03 NA
Baseline 25(OH)D (nmol/L)
<25 92; 3 14/33·0 (0·42) 6/32·2 (0·19) 0·33 (0·11–0·98) 0·046 0·25
≥25 764; 6 107/233·8 (0·46) 79/240·2 (0·33) 0·77 (0·58–1·03) 0·08 ··
Age (years)
<16 290; 5 26/57·6 (0·45) 19/61·8 (0·31) 0·64 (0·34–1·20) 0·16 0·56
≥16 665; 3 95/227·2 (0·42) 66/224·7 (0·29) 0·70 (0·51–0·97) 0·03 ··
Sex
Female 547; 7 80/163·6 (0·49) 47/167·7 (0·28) 0·61 (0·43–0·88) 0·008 0·17
Male 408; 7 41/121·1 (0·34) 38/118·9 (0·32) 0·91 (0·58–1·42) 0·67 ··
Ethnic or racial origin
African-American, Afro-Caribbean, 
or black African origin
154; 3 28/46·4 (0·60) 14/43·4 (0·32) 0·54 (0·29–1·03) 0·06 0·32
Asian origin 207; 5 6/42·0 (0·14) 4/48·5 (0·08) 0·81 (0·19–3·51) 0·78 ··
White European origin 520; 5 80/177·8 (0·45) 59/172·3 (0·34) 0·79 (0·56–1·11) 0·17 ··
Other or mixed 74; 3 7/18·6 (0·38) 8/22·3 (0·36) 0·88 (0·31–2·53) 0·81 ··
Weight
Not overweight 381; 7 38/110·5 (0·34) 26/104·5 (0·25) 0·91 (0·55–1·51) 0·71 0·31
Overweight§ 574; 7 83/174·3 (0·48) 59/182·0 (0·32) 0·68 (0·49–0·95) 0·02 ··
Bolus-dose vitamin D given
No 275; 4 13/53·8 (0·24) 10/58·9 (0·17) 0·65 (0·26–1·63) 0·36 0·49
Yes 680; 3 108/230·9 (0·47) 75/227·6 (0·33) 0·71 (0·52–0·95) 0·02 ··
Daily dose equivalent (IU)
<2000 258; 4 13/52·1 (0·25) 10/58·6 (0·17) 0·62 (0·26–1·44) 0·26 0·78
≥2000 697; 3 108/232·7 (0·46) 75/228·0 (0·33) 0·73 (0·54–0·98) 0·03 ··
Received inhaled corticosteroids
No 92; 4 1/18·8 (0·05) 4/26·1 (0·15) 1·11 (0·07–18·40) 0·94 0·19
Yes 764; 5 120/248·0 (0·48) 81/246·3 (0·33) 0·71 (0·54–0·95) 0·02 ··
Study duration (months)
<6 138; 2 13/25·0 (0·52) 9/19·4 (0·46) 0·50 (0·18–1·37) 0·18 0·62
≥6 816; 5 108/259·8 (0·42) 76/267·2 (0·28) 0·72 (0·53–0·96) 0·03 ··
NA=not applicable. IU=international unit. 25(OH)D=25-hydroxyvitamin D. *Some trials did not contribute data to a given subgroup, either because individuals within that 
subgroup were not represented or because data relating to the potential effect modifier were not available, accordingly the number of trials represented varies between 
subgroups. †Adjusted for age and sex. ‡pinteraction values are between adjusted rate ratios in the subgroup. §Overweight defined as body-mass index Z score of 1·0 or more for 
participants younger than 19 years and as body-mass index of 25 kg/m² or more for participants aged 19 years or older.
Table 2: One-step individual participant data meta-analysis of rate of asthma exacerbations requiring treatment with systemic corticosteroids
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subgroup effects were downgraded to moderate due to 
their relative imprecision (appendix p 5).
An exploratory analysis testing the effects of 
vitamin D supplementation in individuals with baseline 
25(OH)D concentrations in the ranges of 25–49·9 nmol/L, 
50–74·9 nmol/L, and 75 nmol/L or higher did not reveal 
evidence of effect modification (pinteraction=0·40) or significant 
protective effects of vitamin D supple mentation within 
these subgroups (subgroup with baseline 25[OH]D of 
25·0–49·9 nmol/L: aIRR 0·79, 95% CI 0·50–1·23 
[306 participants in six studies; within subgroup p=0·29]; 
subgroup with baseline 25[OH]D of 50·0–74·9 nmol/L: 
aIRR 0·76, 0·48–1·22 [334 participants in six studies; 
within subgroup p=0·26]; subgroup with baseline 
25[OH]D of 75 nmol/L or higher: aIRR 0·79, 0·37–1·69 
[120 participants in five studies; within subgroup p=0·54]; 
figure 3). p values for interaction for all other subgroup 
analyses were also higher than 0·05 (table 2; appendix p 7 
for end-study 25[OH]D level pairwise analyses).
Results of the one-step IPD meta-analysis of secondary 
efficacy outcomes are presented in table 3. Vitamin D 
supplementation reduced the proportion of people with 
at least one asthma exacerbation resulting in emergency 
department attendance or hospital admission, or both 
(aOR 0·46, 95% CI 0·24–0·91; 955 participants in 
seven studies; p=0·03). No significant effect of vitamin D 
supplementation was seen on risk of having at least one 
asthma exacerbation as defined in the protocols of 
primary RCTs (aOR 0·81, 0·58–1·11; 955 participants in 
seven studies; p=0·19).
Results of the one-step IPD meta-analysis of safety 
outcomes are also reported in table 3. No participant had 
hypercalcaemia or renal stones. Vitamin D supple-
mentation did not affect the risk of having at least one 
serious adverse event of any cause (aOR 0·87, 95% CI 
0·46–1·63; 955 participants in seven studies; p=0·66). 
Only one trial participant died, which was due to a road 
traffic accident.
A funnel plot for the outcome of rate of asthma 
exacerbations treated with systemic corticosteroids did 
not suggest publication bias in relation to this outcome 
because the smaller RCTs showed equal spread of results 
on both sides of the overall adjusted rate ratio (appendix 
p 10). No relation between effect size and study size was 
apparent (appendix p 6).
Discussion
We report results of the first IPD meta-analysis of RCTs of 
vitamin D to reduce the risk of asthma exacerbations. In 
the study population as a whole, vitamin D supplementation 
reduced the rate of asthma exacerbations treated with 
systemic corticosteroids, as compared with placebo 
(0·30 events per person per year vs 0·43 events per person 
per year; p=0·03), and the proportion of people having at 
least one exacerbation requiring emergency department 
attendance or hospital admission, or both (3% vs 6%; 
p=0·03). Subgroup analyses revealed that reductions in 
exacerbation rate with vitamin D were statistically 
significant in par ticipants with baseline circulating 
25(OH)D concen tration levels less than 25 nmol/L, but not 
in people with baseline levels of 25(OH)D of 25 nmol/L or 
Figure 2: Two-step individual participant data meta-analysis, event rate for asthma exacerbations requiring treatment with systemic corticosteroids
Weights are from the random-effects analysis. No asthma exacerbations requiring treatment with systemic corticosteroids arose in the trials by Urashima and 
colleagues9 and Majak and colleagues.10 Only one such event arose in the trial by Tachimoto and colleagues;14 as such, an adjusted incidence rate ratio could not be 
calculated for this study.
Figure 3: Effects of vitamin D supplementation on asthma exacerbation rate 
by baseline circulating 25(OH)D concentration categorised by 25 nmol/L 
strata
Shown are the results of one-step individual participant data meta-analysis. 
The incidence rate ratio is adjusted for age and sex. Mean and 95% CI are 
presented. 25(OH)D=25-hydroxyvitamin D.
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higher. Vitamin D supplementation was safe at the doses 
administered: no instances of hypercalcaemia or renal 
stones were seen, and serious adverse events were evenly 
distributed between participants randomly assigned to 
vitamin D versus placebo.
Our findings from analysing the study population as a 
whole are consistent with those of our recent aggregate 
data meta-analysis of RCTs of vitamin D for the 
management of asthma, which reported protective effects 
against asthma exacerbations treated with systemic 
corticosteroids of similar magnitude (IRR 0·64, 95% CI 
0·46–0·90).20 The present study represents a significant 
advance because access to IPD has allowed us to do 
subgroup analyses to assess whether specific factors 
modify the effects of vitamin D supplementation on risk 
of asthma exacerbations. We hypothesised that the 
protective effects of vitamin D supplementation against 
asthma exacerbation would be strongest in participants 
with the lowest baseline vitamin D status, as has been 
previously reported for the outcome of acute respiratory 
infection.23 We saw a statistically significant rate reduction 
in participants with baseline 25(OH)D of less than 
25 nmol/L, but not in participants with 25(OH)D of 
25 nmol/L or higher. However, the p value for interaction 
for this subgroup analysis was non-significant 
(pinteraction=0·25); formally, therefore, we have not shown 
that effects are stronger in one group than in the other. 
p values for interaction were also higher than 0·05 for 
subgroup analyses relating to age, sex, racial or ethnic 
origin, body weight, vitamin D dosing regimen, use of 
inhaled corticosteroids, and study duration. These factors 
might not modify the effects of vitamin D supplementation 
on exacerbation risk; alternatively, we might have lacked 
statistical power to detect the relevant interactions. 
Several additional RCTs are ongoing (eg, NCT01419262, 
NCT01728571, NCT02197702, and NCT02424552), and, in 
due course, we hope to include IPD from these studies in 
an updated meta-analysis, increasing the power for sub-
group analyses.
Although vitamin D reduced the risk of asthma 
exacerbations requiring treatment with systemic 
corticosteroids, no significant effect was seen on the risk 
of asthma exacerbations as originally defined in the 
protocols of the primary trials. In the majority of trials, 
the original definition of exacerbation was broader than 
the one prespecified for this meta-analysis—
eg, encompassing events that resulted in dips in peak 
expiratory flow rate or FEV1 that were not treated 
with systemic corticosteroids.11,12 Differing efficacies of 
vitamin D supplementation for these two outcomes 
might suggest that this intervention specifically reduces 
risk of more serious exacerbations. Alternatively, less 
stringent definitions of exacerbation in primary trial 
protocols might have resulted in a degree of 
misclassification with a consequent increase in noise: 
signal ratio that might have obscured a real effect of 
vitamin D on exacerbation risk.
Our study has several strengths. The included studies 
were of high quality, and of sufficient duration for steady-
state 25(OH)D concentrations to be attained among 
participants randomly assigned to receive vitamin D3. 
The proportion of randomly assigned participants with 
missing outcome data was small (2·4%), and 25(OH)D 
concentrations were measured using validated assays 
in laboratories that participated in external quality 
assessment schemes. The analysis contained participants 
with diverse characteristics in multiple settings, 
incorporating new data from a trial16 done in children 
with severe asthma that was published after the date of 
the final literature search for our previous aggregate data 
meta-analysis.20 Our findings therefore have a high 
degree of internal and external validity.
Our study also has some limitations. We did not obtain 
IPD for one eligible trial;13 however, this study was 
relatively small (n=100) and has previously been assessed 
as being at high risk of bias.20 Notably, this study reported 
strong protective effects of vitamin D against asthma 
exacerbation;13 as such, if exclusion of its findings leads to 
a bias, it is likely to be a bias towards the null. 
Interpretation of the funnel plot (appendix p 10) is limited 
by the small number of studies included, but the fact that 
the smaller RCTs showed an equal spread of results on 
Number of 
participants; 
number of trials*
Participants with 
one or more event 
(control group)
Participants with 
one or more event 
(intervention group)
Adjusted odds 
ratio (95% CI)*
p value
Asthma exacerbation resulting in emergency 
department attendance or hospital admission, or both
955; 7 28/480 (6%) 14/475 (3%) 0·46 (0·24–0·91) 0·03
Asthma exacerbation as defined in primary trial 955; 7 123/480 (26%) 105/475 (22%) 0·81 (0·58–1·11) 0·19
Serious adverse event of any cause 955; 7 22/480 (5%) 20/475 (4%) 0·87 (0·46–1·63) 0·66
Hypercalcaemia 955; 7 0/480 (0%) 0/475 (0%) ·· ··
Renal stones 955; 7 0/480 (0%) 0/475 (0%) ·· ··
Death due to asthma exacerbation 955; 7 0/480 (0%) 0/475 (0%) ·· ··
Death due to any cause 955; 7 0/480 (0%) 1/475 (<1%)† ·· ··
*Adjusted for age, sex, and duration of participant follow-up. †Death due to road traffic accident.
Table 3: One-step individual participant data meta-analysis of secondary outcomes
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both sides of the overall adjusted rate ratio provides some 
reassurance that publication bias was not a major issue in 
our meta-analysis; an impression that is reinforced by the 
absence of an association between effect size and study 
size (appendix p 6). Power for some subgroup analyses 
was limited; this is an inescapable problem in view of the 
small number of published RCTs in this field. Where 
95% CI for estimates of effect from subgroup analyses 
were wide, we downgraded our quality assessment of 
subgroup findings to moderate (appendix p 5).
In conclusion, our IPD meta-analysis confirms results 
from our previous aggregate data meta-analysis showing 
that vitamin D supplementation safely reduces the rate of 
asthma exacerbations overall. However, we did not find 
definitive evidence that effects of this intervention differed 
across subgroups of patients. In view of the low cost of this 
intervention and the major economic burden associated 
with asthma exacerbations, vitamin D supplementation 
represents a potentially cost-effective strategy to reduce 
this important cause of morbidity and mortality.
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